Bio Korea represents a strategic step forward in the two companies’ ongoing expansion into the Asian market, building on an established global client base there and across Europe and the US. Together, Clean Cells and Naobios collaborate to offer seamless European CRO and CDMO solutions that combine GMP manufacturing and QC (quality control) for viral products, providing a complete end-to-end service offer that is rare in this market.

Clean Cells is targeting South Korea, a fast-growing hub for cell and gene therapy and vaccines. The cell and gene therapy manufacturing market in South Korea is expected to reach a projected revenue of $1.5 billion by 2030. Clean Cells’ GMP QC and analytical services support the country’s expanding biopharma sector while reducing regulatory risk for companies seeking global approval of biologics and ATMPs.

With more than 25 years of experience, Clean Cells covers the full development continuum from early R&D to the commercial GMP stage and all major biological modalities, including viral products, cell and gene therapies, vaccines, mAbs and recombinant proteins. Its capabilities span viral safety and identity testing, genetic stability, purity testing and replication-competent particle detection; with internationally recognized expertise that is EMA GMP-certified and FDA-inspected.

“South Korea is one of the most dynamic CGT and vaccine markets in Asia. We are delighted to attend Bio Korea to meet existing and future clients and strengthen our long-term commitment in the country and more widely in Asia,” said François Pedelaborde, business development director at Clean Cells.

Naobios, with over 20 years of experience in viral vaccines and bioproduction, will present its GMP clinical batch manufacturing of viral vaccines (BSL2 and BSL3 certified facilities, up to 200L bioreactors), alongside the bioproduction of oncolytic viruses, viral vectors and exosomes. From proof-of-concept to Phase 3 and then to commercial manufacturing, Naobios provides full support from upstream and downstream process development to final Drug Product.

Naobios already has a proven track record in South Korea and the broader Asian market alongside its partner Sumagen (currently, Creo SG Co.,Ltd.), for whom it is optimizing an HIV vaccine candidate for industrial production (BSL3). The company also has a contract with the Tokyo Metropolitan Institute of Medical Science, Japan, to develop a new live-attenuated vaccine against mpox, and supports international companies through its US partnerships with FluGen and the Gates Foundation.

“Creo SG has collaborated with Naobios, through Sumagen Canada Inc., on HIV vaccine production. Naobios possesses differentiated BSL3 facilities and advanced technical capabilities, and its close, efficient communication enables proactive and effective problem-solving. In addition, the group’s in-house analytical capabilities enhance overall production efficiency,” said Seung Ho Choo, Executive Director of R&D at Creo SG Co., Ltd.

Clean Cells and Naobios representatives will be available in Seoul from April 24 for meetings, and during the Bio Korea event at booth #F32.